Characterisation of tetraspanins from Schistosoma haematobium and evaluation of their potential as novel diagnostic markers.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 19 10 2021
accepted: 06 01 2022
revised: 03 02 2022
pubmed: 25 1 2022
medline: 17 2 2022
entrez: 24 1 2022
Statut: epublish

Résumé

Schistosoma haematobium is the leading cause of urogenital schistosomiasis and it is recognised as a class 1 carcinogen due to the robust association of infection with bladder cancer. In schistosomes, tetraspanins (TSPs) are abundantly present in different parasite proteomes and could be potential diagnostic candidates due to their accessibility to the host immune system. The large extracellular loops of six TSPs from the secretome (including the soluble excretory/secretory products, tegument and extracellular vesicles) of S. haematobium (Sh-TSP-2, Sh-TSP-4, Sh-TSP-5, Sh-TSP-6, Sh-TSP-18 and Sh-TSP-23) were expressed in a bacterial expression system and polyclonal antibodies were raised to the recombinant proteins to confirm the anatomical sites of expression within the parasite. Sh-TSP-2, and Sh-TSP-18 were identified on the tegument, whereas Sh-TSP-4, Sh-TSP-5, Sh-TSP-6 and Sh-TSP-23 were identified both on the tegument and internal tissues of adult parasites. The mRNAs encoding these TSPs were differentially expressed throughout all schistosome developmental stages tested. The potential diagnostic value of three of these Sh-TSPs was assessed using the urine of individuals (stratified by infection intensity) from an endemic area of Zimbabwe. The three Sh-TSPs were the targets of urine IgG responses in all cohorts, including individuals with very low levels of infection (those positive for circulating anodic antigen but negative for eggs by microscopy). This study provides new antigen candidates to immunologically diagnose S. haematobium infection, and the work presented here provides compelling evidence for the use of a biomarker signature to enhance the diagnostic capability of these tetraspanins.

Identifiants

pubmed: 35073344
doi: 10.1371/journal.pntd.0010151
pii: PNTD-D-21-01523
pmc: PMC8812969
doi:

Substances chimiques

Antibodies, Helminth 0
Antigens, Helminth 0
Helminth Proteins 0
Tetraspanins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0010151

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Parasitol. 2010 Apr;40(5):543-54
pubmed: 19853607
PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2428
pubmed: 24069483
N Engl J Med. 2002 Apr 18;346(16):1212-20
pubmed: 11961151
Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):167-9
pubmed: 8337718
Lancet. 2014 Jun 28;383(9936):2253-64
pubmed: 24698483
PLoS Negl Trop Dis. 2019 May 28;13(5):e0007450
pubmed: 31136572
Proteomics. 2010 Mar;10(5):1063-78
pubmed: 20049860
Eur J Immunol. 1991 Feb;21(2):377-83
pubmed: 1842498
Lancet Microbe. 2021 Nov;2(11):e617-e626
pubmed: 34977830
Clin Microbiol Rev. 2001 Apr;14(2):270-95
pubmed: 11292639
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W557-9
pubmed: 15980534
Trans R Soc Trop Med Hyg. 2007 May;101(5):433-8
pubmed: 17064746
Am J Trop Med Hyg. 2005 Mar;72(3):311-9
pubmed: 15772328
Lancet Infect Dis. 2016 Aug;16(8):971-9
pubmed: 27197551
Vaccine. 2019 Oct 8;37(43):6500-6509
pubmed: 31515141
Trends Parasitol. 2009 Apr;25(4):151-6
pubmed: 19269899
Int J Parasitol. 2016 Jan;46(1):1-5
pubmed: 26460238
Ann Intern Med. 2019 May 21;170(10):732-733
pubmed: 30615787
PLoS Negl Trop Dis. 2009 Nov 03;3(11):e543
pubmed: 19885392
Parasitol Res. 2018 Nov;117(11):3625-3631
pubmed: 30178196
Parasit Vectors. 2012 Dec 21;5:298
pubmed: 23259435
Am J Trop Med Hyg. 2020 Jul;103(1_Suppl):50-57
pubmed: 32400344
Parasitology. 2014 Dec;141(14):1841-55
pubmed: 24932595
Int J Parasitol. 2007 Mar;37(3-4):257-63
pubmed: 17222846
PLoS Pathog. 2010 Apr 15;6(4):e1000840
pubmed: 20419145
J Infect Dis. 2015 Nov 15;212(10):1636-45
pubmed: 25985904
PLoS Negl Trop Dis. 2015 May 14;9(5):e0003752
pubmed: 25973845
Parasite Immunol. 2003 Aug-Sep;25(8-9):429-37
pubmed: 14651590
Vaccine. 2009 Dec 9;27(52):7339-45
pubmed: 19782112
Clin Vaccine Immunol. 2009 Dec;16(12):1796-803
pubmed: 19812258
Mol Cell Proteomics. 2006 Feb;5(2):347-56
pubmed: 16269422
Mol Cell Probes. 2011 Aug;25(4):143-52
pubmed: 21651977
Acta Trop. 2003 May;86(2-3):125-39
pubmed: 12745133
Parasitol Res. 2011 Jan;108(1):115-21
pubmed: 20852891
Vaccines (Basel). 2020 Jul 24;8(3):
pubmed: 32722279
Int J Parasitol. 2015 Jul;45(8):505-16
pubmed: 25910674
Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296
pubmed: 33885785
Trop Med Int Health. 2011 Sep;16(9):1099-103
pubmed: 21692957
PLoS Negl Trop Dis. 2011;5(5):e1166
pubmed: 21655308
Nat Med. 2006 Jul;12(7):835-40
pubmed: 16783371
Parasit Vectors. 2011 Sep 29;4:190
pubmed: 21958506
Curr Protoc Immunol. 2013 Nov 18;103:19.1.1-19.1.58
pubmed: 24510597
Infect Dis Clin North Am. 2012 Jun;26(2):383-97
pubmed: 22632645
PLoS Negl Trop Dis. 2014 Jul 24;8(7):e2865
pubmed: 25058013
Mem Inst Oswaldo Cruz. 2002;97 Suppl 1:167-9
pubmed: 12426614
Travel Med Infect Dis. 2011 Jan;9(1):6-24
pubmed: 21216199
Cell Mol Life Sci. 2001 Aug;58(9):1189-205
pubmed: 11577978
Acta Trop. 2000 Oct 23;77(1):41-51
pubmed: 10996119
Nat Rev Dis Primers. 2018 Aug 9;4(1):13
pubmed: 30093684
Nat Rev Immunol. 2005 Feb;5(2):136-48
pubmed: 15688041
PLoS Negl Trop Dis. 2012;6(3):e1564
pubmed: 22428079
Mol Biochem Parasitol. 2006 May;147(1):109-17
pubmed: 16540186
Lancet. 2006 Sep 23;368(9541):1106-18
pubmed: 16997665
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Proteome Res. 2005 May-Jun;4(3):958-66
pubmed: 15952743
Proteomics. 2006 Mar;6(5):1471-82
pubmed: 16447162
PLoS Negl Trop Dis. 2012;6(12):e1939
pubmed: 23236532
Lancet Infect Dis. 2006 Jul;6(7):411-25
pubmed: 16790382
Annu Rev Cell Dev Biol. 2003;19:397-422
pubmed: 14570575
Front Immunol. 2018 Apr 30;9:850
pubmed: 29760697
Parasitol Today. 1998 Mar;14(3):99-104
pubmed: 17040715
PLoS Negl Trop Dis. 2019 May 15;13(5):e0007362
pubmed: 31091291
Trop Med Parasitol. 1992 Sep;43(3):149-54
pubmed: 1470831
Parasite Immunol. 2014 Sep;36(9):428-38
pubmed: 25201406
Trans R Soc Trop Med Hyg. 2006 Sep;100(9):847-54
pubmed: 16443246
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Sci Rep. 2017 Oct 30;7(1):14342
pubmed: 29084967

Auteurs

Gebeyaw G Mekonnen (GG)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Department of Medical Parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Bemnet A Tedla (BA)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.

Mark S Pearson (MS)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.

Luke Becker (L)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.

Matt Field (M)

Australian Institute of Tropical Health & Medicine and Centre for Tropical Bioinformatics and Molecular Biology, James Cook University, Cairns, Australia.
Immunogenomics Lab, Garvan Institute of Medical Research, Darlinghurst, Australia.
Menzies School of Health Research, Charles Darwin University, Darwin, Australia.

Abena S Amoah (AS)

Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Malawi Epidemiology and Intervention Research Unit, Chilumba, Malawi.

Govert van Dam (G)

Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.

Paul L A M Corstjens (PLAM)

Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.

Takafira Mduluza (T)

Biochemistry Department, University of Zimbabwe, P.O. Box MP167, Mount Pleasant, Harare, Zimbabwe.
Tackling Infections to Benefit Africa Partnership, NIHR Global Health Research Unit, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.

Francisca Mutapi (F)

Tackling Infections to Benefit Africa Partnership, NIHR Global Health Research Unit, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.
Institute of Immunology & Infection Research, Ashworth Laboratories, University of Edinburgh, King's Buildings, Edinburgh, United Kingdom.

Alex Loukas (A)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.

Javier Sotillo (J)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH